Highest adverse effect rates for three drugs in parkinson's

September 21, 2017

(HealthDay)—Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics.

Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a to compare the of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials.

The researchers found that, compared with placebo, the incidence of of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent).

"In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

Explore further: Continuing statin after adverse Rx tied to lower cardiac risk

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Continuing statin after adverse Rx tied to lower cardiac risk

July 25, 2017
(HealthDay)—For patients with an adverse reaction to a statin, continued statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published online July 25 in the ...

Low incidence of adverse events for A-fib catheter ablation

September 4, 2017
(HealthDay)—The incidence of adverse events (AEs) is low for patients undergoing catheter ablation (CA) for atrial fibrillation (AF), according to a study published online Aug. 30 in JACC: Clinical Electrophysiology.

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

Findings support lower doses of atropine in pediatric myopia Rx

May 18, 2017
(HealthDay)—Adverse effects are less frequent at lower doses of atropine, and higher doses are not more effective in reducing progression of myopia in children, according to a meta-analysis published online May 11 in JAMA ...

Benefits of continued statin use after adverse reactions

July 24, 2017
Statins are known to reduce the risk of death and cardiovascular events for people who are at high risk; however, as many as 75 percent of patients discontinue statin therapy within two years, often after reporting an adverse ...

Recommended for you

Eating yogurt may reduce cardiovascular disease risk

February 15, 2018
A new study in the American Journal of Hypertension, published by Oxford University Press, suggests that higher yogurt intake is associated with lower cardiovascular disease risk among hypertensive men and women.

Newly discovered gene may protect against heart disease

February 14, 2018
Scientists have identified a gene that may play a protective role in preventing heart disease. Their research revealed that the gene, called MeXis, acts within key cells inside clogged arteries to help remove excess cholesterol ...

Blood thinners may raise stroke risk in over-65s with kidney disease

February 14, 2018
People over 65 years old may be increasing their stroke risk by taking anticoagulants for an irregular heartbeat if they also have chronic kidney disease, finds a new study led by UCL, St George's, University of London and ...

Cardiac macrophages found to contribute to a currently untreatable type of heart failure

February 14, 2018
A team of Massachusetts General Hospital (MGH) investigators has discovered, for the first time, that the immune cells called macrophages contribute to a type of heart failure for which there currently is no effective treatment. ...

Study maps molecular mechanisms crucial for new approach to heart disease therapy

February 13, 2018
Creating new healthy heart muscle cells within a patient's own ailing heart. This is how scientists hope to reverse heart disease one day. Today, a new study led by UNC-Chapel Hill researchers reveals key molecular details ...

Quality toolkit improves care in Indian hospitals

February 13, 2018
A simple toolkit of checklists, education materials and quality and performance reporting improved the quality of care but not outcomes in hospitals in the south Indian state of Kerala and may have the potential to improve ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.